Diagnosis and treatment of chronic lymphocytic leukemia: a review
M Shadman - Jama, 2023 - jamanetwork.com
Importance Chronic lymphocytic leukemia (CLL), defined by a minimum of 5× 10 9/L
monoclonal B cells in the blood, affects more than 200 000 people and is associated with …
monoclonal B cells in the blood, affects more than 200 000 people and is associated with …
Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia
R Bennett, MA Anderson, JF Seymour - Journal of Hematology & Oncology, 2023 - Springer
Background The treatment landscape for chronic lymphocytic leukemia (CLL) continues to
undergo considerable evolution. Optimal selection of initial therapy from multiple effective …
undergo considerable evolution. Optimal selection of initial therapy from multiple effective …
[HTML][HTML] Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia
Background Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic
lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase …
lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase …
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial
O Al-Sawaf, R Ligtvoet, S Robrecht, J Stumpf… - Nature medicine, 2024 - nature.com
In patients with chronic lymphocytic leukemia, Richter transformation (RT) reflects the
development of an aggressive lymphoma that is associated with poor response to …
development of an aggressive lymphoma that is associated with poor response to …
Zanubrutinib: past, present, and future
In recent years, Bruton tyrosine kinase (BTK) inhibitors have provided significant advances
in the treatment of patients with B-cell malignancies. Ibrutinib was the first BTK inhibitor to be …
in the treatment of patients with B-cell malignancies. Ibrutinib was the first BTK inhibitor to be …
Small molecule inhibitors targeting the cancers
Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …
Chronic lymphocytic leukemia treatment algorithm 2022
PJ Hampel, SA Parikh - Blood cancer journal, 2022 - nature.com
The treatment landscape for patients with chronic lymphocytic leukemia (CLL) has changed
considerably with the introduction of very effective oral targeted therapies (such as Bruton …
considerably with the introduction of very effective oral targeted therapies (such as Bruton …
[HTML][HTML] From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia
P Abrisqueta, F Nadeu, J Bosch-Schips… - Cancer Treatment …, 2023 - Elsevier
Richter transformation (RT) refers to the progression of chronic lymphocytic leukemia, the
most prevalent leukemia among adults, into a highly aggressive lymphoproliferative …
most prevalent leukemia among adults, into a highly aggressive lymphoproliferative …
Advancements in the treatment of CLL: The rise of zanubrutinib as a preferred therapeutic option
Simple Summary Due to improved selectivity and favorable toxicity profiles, the next-
generation Bruton's tyrosine kinase inhibitors (BTKis) are replacing ibrutinib in the treatment …
generation Bruton's tyrosine kinase inhibitors (BTKis) are replacing ibrutinib in the treatment …
Outcomes in patients with high-risk features after fixed-duration ibrutinib plus venetoclax: phase II CAPTIVATE study in first-line chronic lymphocytic leukemia
Purpose: The CAPTIVATE study investigated first-line ibrutinib plus venetoclax for chronic
lymphocytic leukemia in 2 cohorts: minimal residual disease (MRD)-guided randomized …
lymphocytic leukemia in 2 cohorts: minimal residual disease (MRD)-guided randomized …